-transparent.png){kind=logo}
The serum concentration of the cell proliferation marker TPS (tissue polypeptide-specific antigen) was compared with the tumour marker PSA (prostate specific antigen). PSA was found elevated in 50% of the benign prostatic hypertrophy (BPH) patients, in 88% of the patients with active prostate cancer and in 40% of the patients who were in an inactive phase. For TPS these values were 6, 34 and 0%, respectively. The metastatic progression was biochemically mirrored by pronounced elevations of PSA and TPS. These data suggest that TPS might be a valuable adjunct in the diagnosis and follow-up of patients with prostate cancer, especially in differentiating benign from malignant deterioration of the disease.
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
March 1992,
The Journal of urology,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
January 1995,
International urology and nephrology,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
January 1992,
European urology,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
January 2014,
Soins. Gerontologie,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
September 1997,
Biulleten' eksperimental'noi biologii i meditsiny,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
January 1996,
Urologia internationalis,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
November 1991,
International journal of cancer,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
May 2015,
Vojnosanitetski pregled,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
January 2000,
Current opinion in urology,
J Marrink, and
R Oosterom, and
H M Bonfrer, and
F H Schröder, and
H J Mensink
July 1995,
Orvosi hetilap,
